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Introduction
Gastric cancer is one of the most common cancers worldwide, and although its incidence has decreased in recent years, it is still high in East Asia, including Japan. Most gastric cancers are sporadic and develop in response to the cumulative effect of environmental risk factors and genetic susceptibility of individuals (1) , but a small subset are aggregated in families. The risk of individuals in families with gastric cancer aggregation is higher than in individuals without familial aggregation (2, 3) . Since the report of the existence of germline mutations that cause loss of function of the CDH1 gene in New Zealand Maori families with diffuse type gastric cancer (4) , germline mutations in the CDH1 gene have been found in gastric cancer families in different ethnic groups (5) (6) (7) (8) (9) (10) (11) . However, the frequency of germline CDH1 mutations is low, even in families with aggregation of gastric cancer (8-10, 12, 13) . Kim et al. recently reported finding a germline missense mutation in the MET receptor thyrosine kinase gene in familial gastric cancer (FGC) patients without a germline CDH1 mutation (14) . The above findings suggest that genetic factors are important to the pathogenesis of gastric cancer with familial aggregation and that germline mutations of genes other than CDH1 may contribute to the development of FGC.
The tumor suppressor protein p53 mediates growth arrest or apoptosis in response to potentially oncogenic cellular stresses such as DNA damage (15, 16) , and loss of p53 function plays a central role in the development of cancer, and is caused by mutations. Many somatic p53 mutations lead to a loss of p53 function and are detected in gastric cancer (17, 18) .
Germline p53 mutations are known to cause Li-Fraumeni syndrome (LFS) (19) (20) (21) , and interestingly, germline p53 mutations have recently been found in European and Korean FGC patients (22) (23) (24) . Since, to our knowledge only three FGC cases with a germline p53 mutation have been reported (22) (23) (24) and none have been in Japanese FGC patients, in the present study we investigated whether germline p53 mutations are responsible for FGC in a Japanese population by screening 35 Japanese FGC families for p53 germline mutations. We identified a p53-p.Val31Ile germline mutation in one family and characterized the p53 mutant.
Materials and Methods

Samples, cell lines, and ethical considerations
In a previous study 80 blood samples were collected from 35 Japanese FGC families, and DNA was extracted (10) . All of the families had been shown to be negative for germline CDH1 mutation (10) . Cell lines H1299 and 293T were purchased from the American Type Culture Collection (Manassas, VA). DNA from specimens of sporadic gastric cancer were collected previously (25, 26) . The research protocol was approved by the Institutional Review Board of Hamamatsu University School of Medicine (12) (13) (14) .
Polymerase chain reaction (PCR) and sequencing analysis
Fragments covering the entire coding exons and boundary regions of the p53 gene were amplified by PCR with HotStarTaq DNA polymerase (QIAGEN, Valencia, CA). The primers 6   TCG CAG CTC TAA TGC CTT C-3' for the BAX promoter, and 5'-TAG CTA GCT AGC TTT   GCG GAG GTT TTG TTG-3' and 5'-AAG ATC TTC GGA AAT CAT GAA ACA TCT GTG G-3' for the MDM2 promoter. To construct p53 expression vector with a retroviral-mediated tetracycline-regulation system, pRevTRE -Tight vector was first constructed by inserting the P tight promoter region amplified from pTRE-Tight vector (Clontech, Mountain View, CA) intro the XhoI and BamHI sites of the pRevTRE vector (Clontech). p53 was then inserted into the pRevTRE -Tight vector at the BamHI site, and the expression vector created was named pRevTRE -Tight p53 vector. pQCXIN-Tet-On retroviral vector was constructed by inserting the Tet-On sequence amplified from the pRevTetOn vector (Clontech) into the BamHI site of pQCXIN retroviral vector (Clontech). The following PCR primers were used: 5'-TCC GCG GAT CCA AGC TTG TTA ATT AAT ATG TC-3' and 5'-TCG ATG TGG ATC CTC GCG CCC CCT ACC CAC-3'. All the plasmid vectors were confirmed by sequencing.
Luciferase reporter assay
A p53-null H1299 human cancer cell line was cotransfected with 1 μg of the p53 expression vector, 300 ng of firefly luciferase reporter vector pGL4.10 containing a fragment of the p21 
Western blot analysis
Cells were harvested in lysis buffer containing 10 mM HEPES (pH7.5), 1.0% Nonidet P-40, 1 mM EDTA, 1 mM DTT, and 0.1 mg/ml PMSF, and the whole-cell extracts were mixed with an equal volume of 2xSDS sample buffer, and boiled. A 25 μg amount of extracts was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the proteins obtained were electrophoretically transferred to a PVDF membrane (GE Healthcare Bio-Science Corp., Piscataway, NJ). The membrane was blocked with nonfat milk and incubated with anti-p53 monoclonal antibody (clone DO7; Novocastra Laboratories, Newcastle, UK). After washing with phosphate-buffered saline containing 0.1% Tween-20 (PBS-T), the membrane was incubated with anti-mouse HRP-conjugated secondary antibody (GE Healthcare Bio-Science Corp). After washing with PBS-T, immunoreactivity was visualized with an ECL chemiluminescence system (GE Healthcare Bio-Science Corp). CTT GTC CTT ACC AG-3', and SSCP was performed as described previously (27) . In brief, PCR products were diluted with loading solution, and after applying them to 8% polyacrylamide gels, the products were electrophoresed at 4°C. The DNA bands obtained were detected by silver staining. Before typing the sporadic gastric cancer cases, bands derived from the DNA of a FGC20 patient that had shifted abnormally in comparison with bands derived from the DNA of cases homozygous for the c.91G allele were confirmed to be the c.91A mutation by sequencing.
Indirect immunofluorescence analysis
Results
Identification of the novel c.91G>A germline mutation of the p53 gene in a Japanese FGC family
We screened for p53 germline mutations by PCR and subsequent sequencing analyses in 80 probands or relatives in 35 Japanese FGC families without germline CDH1 mutations, and 11 variations were found in the p53 gene locus. When we defined a germline mutation as a gene variation not registered on the dbSNP homepage of the NCBI web site (http://www.ncbi.nlm.nih.gov/SNP/), a database of Japanese single nucleotide polymorphisms (JSNP) (31) , and the genetic polymorphism data of the IARC TP53 mutation database (http://www-p53.iarc.fr/PolymorphismView.asp) (32), three p53 variations were classified as a germline mutation and each was found in unrelated families (Table I) . One of them, the c.91G>A mutation located in exon 3, was detected only in the proband of the family with the identification (ID) number FGC20 who was a heterozygote, and the mutation leads to an amino acid substitution of isoleucine for valine in codon 31 ( Figure 1A ). Two members of the family FGC20 had gastric cancer, and the proband was diagnosed with five synchronous colon cancers at 42 years of age ( Figure 1B) . Interestingly, there were two members with hepatocellular carcinoma and two members with uterine cancer in the same family. Unfortunately, no samples from family members other than the proband were available for genetic testing for the p53 mutation. Detection of the c.91G>A mutation was previously reported as a somatic mutation in lung cancer (33), and has never been reported as a germline mutation. Nor has it never been registered on the dbSNP or JSNP homepages as described above, implying that it is a novel germline mutation. The following eight p53 gene variations besides the germline mutation were detected in our analysis: c.74+38G>C (dbSNP ID = rs1642785), c.96+16_96+31dup16 (rs17878362), c.97-29C>A (rs17883323), c.215G>C (rs1042522), c.672+62G>A (rs1625895), c.782+72C>T (rs12947788), c.782+92T>G (rs12951053), and c.1101-221G>A (rs6503048). One of them, the c.215G>C variation, was associated with an amino acid substitution (p.Arg72Pro), and the Arg72-type was shown to be more susceptible than the Pro72-type to degradation by the E6 following human papilloma virus infection (34).
The c.96+16_96+31dup16 variant type was shown to be associated with a reduced level of p53 mRNA (35). However, both c.215G>C and c.96+16_96+31dup16 are common genetic polymorphisms (35). The others were located in the intron, and as far as we know their functional effect has never been reported. These findings suggested that the p53-c.91G>A
(p.Val31Ile) mutation specifically found in the Japanese FGC family is a novel germline mutation.
Low transcriptional activation function of the Ile31-type p53
To evaluate the functional effect of the p.Val31Ile mutation, we first examined the transcriptional activation potential of the Ile31-type, because the mutation is located in the transactivation domain of p53 protein. (Figure 2 ). These results suggested that Ile31-type p53 has low transcriptional activity in relation to a subset of p53-responsive promoters.
Establishment of p53-inducible cell line
To precisely characterize the p.Val31Ile mutation, we decided to establish cell lines expressing various types of p53 under the control of Dox. First, p53-null human cell line H1299 was infected with virus-containing supernatants from 293T cells cotransfected with pQCXIN-Tet-On and pCL10A1 plasmids, and cells were selected with G418. Next, the stable H1299-Tet-On cell line produced was infected with virus-containing supernatants from 293T 
Low ability of the Ile31-type p53 protein to suppress cell proliferation
Cell proliferation suppressing activity is one of the major activities of p53 protein (15, 16) , and we used the H1299-Tet-On-p53 cell lines to compare the cell proliferation suppressing activity of wt p53 and Ile31-type p53. Cells were plated in medium with or without Dox, and 72 hr later the number of viable cells was counted by measuring the reduction of the tetrazolium monosodium salt WST-8. In the absence of Dox, the number of viable H1299-Tet-On-wt p53 cells and H1299-Tet-On-Ile31-type p53 cells was similar ( Figure 4A ). However, in the presence of Dox, there were significantly fewer viable H1299-Tet-On-wt p53 cells than H1299-Tet-On-Ile31-type p53 cells ( Figure 4B ). These results suggested that Ile31-type p53 has lower cell proliferation suppressing activity than wt p53.
Frequency of the c.91G>A (p.Val31Ile) germline mutation in sporadic gastric cancer
To more clearly demonstrate that the c.91G>A (p.Val31Ile) germline mutation associated with low p53 activity is specific to the FGC20 family, we genotyped DNA from the blood of 110 sporadic gastric cancer patients for the mutation by PCR-SSCP analysis. The c.91G>A mutation was not found in any of them (data not shown), suggesting that the c.91G>A germline mutation is specific to a family with gastric cancer clustering.
Discussion
Sequencing analysis for germline p53 mutations was performed in 80 individuals from 35
Japanese FGC families without germline CDH1 mutations, and one missense (c.91G>A: p.Val31Ile) and two intronic germline mutations were found. The missense mutation of p.Val31Ile was detected as a heterozygote in only the proband from one FGC family, and is a novel germline p53 mutation. The functional effect of the p.Val31Ile mutation was then examined to investigate the role of the p.Val31Ile mutation in the familial clustering of cancers.
A luciferase reporter assay showed that transcriptional activity on p21 and MDM2 promoters but not the BAX promoter was significantly lower in those with Ile31-type p53 than wt p53.
Next, by applying a retrovirus-mediated gene transfer system to p53-null human cell line H1299, we established a stable cell line H1299 expressing p53 under Dox control. Expression of p53 protein was regulated by addition of Dox at a similar level of the Western blot analysis, and nuclear p53 expression was confirmed by immunofluorescence analysis. A cell proliferation assay of Ile31-type p53 showed significantly lower cell proliferation suppressing activity than wt p53. These results suggest that Ile31-type p53 may be partly involved in FGC because of its low transcriptional activity and low cell proliferation suppressing activity in comparison with wt p53.
There have been three reports of FGC families in which a germline mutation of the p53 gene has been identified in Europe and Korea (22) (23) (24) . One of the families meets the clinical criteria for LFS (24) , but, the other two do not (22, 23) . LFS is a cancer predisposition syndrome associated with sarcoma, breast cancer, brain tumors, leukemia, adrenocortical carcinoma, melanoma, and other cancers, including gastric cancer (19) (20) (21) . However, because of the relatively low frequency of gastric cancer in LFS families with the characteristics of both LFS and FGC are thought to be rare, and in fact, the case described above is the only one even reported (24) . On the other hand, when our Japanese case is added to the previous two German and Portuguese cases (22, 23) , the number of FGC families with a germline p53 mutation that do not meet the clinical criteria for LFS rise to three. As regards frequency of the detection of FGC with a germline p53 mutation, according to the previous papers (22, 23) and the present paper one FGC with a germline p53 mutation was found in 35 Japanese families with FGC, one among 34 German families with FGC, and one among 10 Portuguese families with FGC. The results of this and previous studies suggested that the p53 gene should be included in genetic testing of FGC families.
p53 plays an important role in the prevention of cancer by functioning in a transcription dependent and independent manner. It functions in a transcription dependent manner as a transcription factor that induces expression of downstream target genes that negatively control cell growth and viability (15, 16) . The luciferase assay in the present study showed that transcriptional activity by Ile31-type p53 on p21 and MDM2 was significantly lower than by wt p53. However, interestingly, the p21-and MDM2-luciferase activity of Ile31-type p53 was higher than that of Ala143-type p53, a well known transcription-deficient mutant. Moreover, BAX-luciferase activity did not differ between wt p53 and Ile31-type p53, in contrast to the extremely low activity of Ala143-type p53. These results suggested that Ile31-type p53 has reduced transcriptional activity in relation to a subset of p53-responsive promoters, and from a different point of view, this means that the Ile31-type p53 retains partial transcriptional activity towards those promoters. The low as opposed to completely abolished activity of Ile31-type p53 may be involved in FGC but not LFS.
When we turned our attention to the difference in activity between Ile31-type p53 and Ala143-type p53, we noted that the transcriptional activity was lower in the Ala143-type than in the Ile31-type, but that they had similar cell proliferation suppressing activity. One possible explanation for this discordance is that the transcriptional activity and cell proliferation suppressing activity levels of p53 mutants are not always parallel, as has been shown previously (38) . If in addition to the results of the current study we compared p53 activities of wt p53, Ile31-type p53, and Ala143-type p53 proteins other than their transcriptional activity and cell proliferation suppressing activity, we would be able to evaluate the level of the mutant p53 protein ability more precisely. That might enable us to better understand the role of Ile31-type p53 in the occurrence of FGC.
In this study we used a retrovirus-mediated gene transfer system to establish The Dox-regulated inducible expression system was therefore adopted to evaluate the function of p53 mutant in our study. Table I 
